Amyloid-Beta Biomarkers

Preparation

Evidence quality

Highlighted claims

• The primary outcomes are morning CSF amyloid-beta 40 and amyloid-beta 42 levels before and after treatment. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The trial collects primary CSF biomarkers by lumbar puncture at month 3 and month 6. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The primary amyloid-beta analysis compares CSF amyloid-beta levels at month 3 and month 6 with paired-sample t-tests. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Additional biomarkers include plasma amyloid-beta and CSF amyloid-beta 38, amyloid-beta 43, total tau, and phosphorylated tau 181. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The alpha threshold for amyloid-beta testing is Bonferroni-corrected to 0.025 because two amyloid-beta parameters are tested. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Participants without required lumbar punctures are excluded from the primary outcome analysis. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial